Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Should You Buy AbbVie in April?

TheMotleyFool

0 0

AbbVie (NYSE: ABBV) is one of those stocks that should be in everyone's portfolio. It's rare to find its mix of growth and value (plus a really good dividend). The pharmaceutical company has enjoyed a run of six consecutive years of double-digit earnings per share (EPS) growth, and management says they expect more of the same this year. Last year, the company posted EPS of $10.52 per share, a rise of more than 18% year over year. AbbVie expects adjusted diluted EPS for full-year 2021 of $12.32 to $12.52. It posted $45.8 billion in revenue last year, an increase of 37.7% year over year on a reported basis.

The company's share price rose 22% over the last year and has been flat over the past month. Is now the time to buy in?

Source Fool.com

Like: 0

ABBV

Share